Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €9.85 EUR
Change Today +0.19 / 1.97%
Volume 0.0
MVR On Other Exchanges
Symbol
Exchange
Stockholm
Frankfurt
As of 3:09 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

medivir ab-b shs (MVR) Snapshot

Open
€9.75
Previous Close
€9.66
Day High
€9.85
Day Low
€9.70
52 Week High
06/13/14 - €15.33
52 Week Low
03/30/15 - €8.04
Market Cap
243.2M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
26.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVIR AB-B SHS (MVR)

Related News

No related news articles were found.

medivir ab-b shs (MVR) Related Businessweek News

No Related Businessweek News Found

medivir ab-b shs (MVR) Details

Medivir AB, a research-based pharmaceutical company, develops and sells pharmaceuticals for the treatment of infectious diseases, osteoarthritis, neuropathic pain, and oncology in the Nordic region. It focuses on the research and development of pharmaceuticals primarily in the hepatitis C area; osteoarthritis; neuropathic pain; respiratory syncytial virus; and HIV/AIDS. The company sells 16 prescription pharmaceuticals under various brands, including Mollipect, Citodon, Digoxin BioPhausia, Egazil, Laxabon, Lithionit, Morfin Special, Nitroglycerin BioPhausia, Paraflex, Probecid, Solvezink, Suscard, Teovent, and Theo-Dur. It has a collaboration agreement with Cancer Research Technology to develop cancer drugs. Medivir AB is headquartered in Stockholm, Sweden.

141 Employees
Last Reported Date: 04/7/15

medivir ab-b shs (MVR) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr1.9M
Compensation as of Fiscal Year 2014.

medivir ab-b shs (MVR) Key Developments

Medivir AB Announces Positive Preclinical Antiviral and Safety Profile of MIV-802

Medivir AB announced that the preclinical antiviral and safety profile of MIV-802, Medivir's nucleotide polymerase inhibitor under development for the treatment of hepatitis C virus (HCV) infection, was presented at The International Liver CongressTM 2015 of the European Association for the Study of the Liver (EASL), taking place in Vienna from April 22-26. The presentation, entitled 'Preclinical characterization of MIV-802, a novel uridine nucleotide HCV NS5B polymerase inhibitor, for treatment of hepatitis C virus infection' (Abstract P0688), outlines the favourable preclinical profile of MIV-802. This includes selective inhibition of the HCV NS5B polymerase by the active metabolite of MIV-802 when compared with several human DNA and RNA polymerases, the potent and selective pan-genotypic inhibition of HCV RNA replication by MIV-802 in vitro, and its low toxicity in a range of in vitro and in vivo studies. The presentation also describes preclinical studies that show the selective delivery of high levels of the active metabolite of MIV-802 to the liver. The data therefore support the continuing development of MIV-802 for the future treatment of HCV infection in combination with other Direct Acting Antivirals (DAAs).

Medivir AB Announces Positive Results for Simeprevir

Medivir AB announced positive results for simeprevir, the NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, at The International Liver CongressTM 2015 of the European Association for the Study of the Liver (EASL) in Vienna. Late-breaking results from the phase III OPTIMIST-1 and OPTIMIST-2 trials highlight the clinical outcomes of simeprevir in an all-oral combination regimen in a wide range of patients with hepatitis C virus (HCV) infection. The results from the OPTIMIST-1 and OPTIMIST-2 trials are the first phase III data to be presented on simeprevir in combination with sofosbuvir (SMV/SOF) in patients with genotype 1 chronic HCV infection, both with and without cirrhosis. Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor developed by Gilead Sciences Inc. OPTIMIST-1 is a phase III, randomized, open-label trial to investigate the efficacy and safety of the all-oral regimen of SMV/SOF among treatment-naïve and treatment-experienced genotype 1 chronic HCV infected patients without cirrhosis. The primary objective was to show superior sustained virologic response (SVR) at 12 weeks after treatment (SVR12) with twelve and 8 weeks of treatment with SMV/SOF versus a historical control (patients previously treated with approved regimens containing a direct-acting antiviral, pegylated interferon and ribavirin). 97% of patients treated with SMV/SOF for 12 weeks (n=150/155) achieved SVR12, which was superior to the SVR12 rate of 87% among the historical control. SVR12 rates of 100% were seen among patients with IL28B CC genotype (n=43/43) and those with baseline NS5A and NS3 Q80K polymorphisms (n=9/9). Patients treated with eight weeks of SMV/SOF achieved an SVR12 rate of 83% (n=128/155), which was not superior to the SVR12 rate of 83% in the historical control. High SVR12 rates were seen among patients with baseline HCV RNA <4 million IU/mL (96%; n=46/48), IL28B CC genotype (93%; n=38/41), patients with genotype 1b HCV infection (92%; n=36/39), and patients without baseline NS5A and Q80K polymorphisms (89%; n=78/88). The most frequently reported adverse events in the 12-week and eight-week treatment arms were headache (14 and 17%, respectively), fatigue (12 and 15%, respectively) and nausea (15 and 9%, respectively). OPTIMIST-2 is a phase III, open-label, single-arm trial to investigate the efficacy and safety of SMV/SOF in treatment-naïve and treatment-experienced genotype 1 chronic HCV infected patients with cirrhosis. The primary objective was to show superior SVR12 with twelve weeks of treatment with SMV/SOF versus a historical control. Twelve (12) weeks of treatment with SMV/SOF resulted in SVR12 rates of 84% (n=86/103), which was superior to the SVR12 rate of 70% in the historical control. Higher SVR12 rates were seen in patients with baseline NS5A polymorphisms with or without NS3 Q80K polymorphisms (100%, n=13/13), patients with albumin 4 g/dL (94%; n=47/50), and treatment-naïve patients (88%; n=44/50). The most common adverse events were fatigue (20%), headache (20%) and nausea (11%).

Medivir AB, Q1 2015 Earnings Call, May 05, 2015

Medivir AB, Q1 2015 Earnings Call, May 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MVR:GR €9.85 EUR +0.19

MVR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MVR.
View Industry Companies
 

Industry Analysis

MVR

Industry Average

Valuation MVR Industry Range
Price/Earnings 2.4x
Price/Sales 1.5x
Price/Book 1.3x
Price/Cash Flow 2.0x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVIR AB-B SHS, please visit www.medivir.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.